Prevention from Doxorubicin Cardiotoxicity by Available Protective Agents in Iran
Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 7, Issue 1
Abstract
Doxorubicin, used in pediatric chemotherapy regimens, has cardiotoxic effects. Dexrazoxane is co-administrated with doxorubicin to prevent its cardiotoxicity. Here we have explored some alternative food or drugs to be used in absence of dexrazoxane since it’s not readily available in Iran at this time. Keywords: Pediatric, chemotherapy, doxorubicin, cardiotoxicity, dexrazoxane, Iran.
Authors and Affiliations
M Shahriari, B Abdolkarimi
Keywords
Related Articles
- EP ID EP363262
- DOI -
- Views 72
- Downloads 0
A Glance at the Cost of Chelation Therapy with Desferal and Exjade in Iran
Background: Thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or partially suppressed. Using injectable iron chelators have been dominating treatment for the iron o...
Solitary Plasmacytoma of the Humerus
This article has no abstract.
Salivary Antioxidant Level in Oral Squamous Cell Carcinoma
Background: Oral cancer is among the 10 most common cancers worldwide with an increasing global incidence. Compromised antioxidant defense system plays a role in occurrence of cancer. This study evaluated the salivary an...
Features of Bone Sarcomas at MAHAK Children Hospital, Tehran, Iran during 2007-2009
Background: Bone sarcomas are the most common malignancies of bone tissues in children, and are classified into two groups as osteosarcoma and Ewing’s Sarcoma. Treatment and prognosis depend on the subtype and grade of t...
Blood Pressure of Children and Adolescents with Sickle Cell Anemia in Basra, Iraq
Background: Blood pressure in patients with sickle cell anemia (SCA) is influenced by autonomic cardiovascular dysfunction, endocrinopathies, nephropathy and nutritional factors. We aimed to evaluate systemic and diastol...